4 December
2024
IXICO PLC
("IXICO" or
the "Company")
Share Option Award &
Director Bed & ISA Dealings
PDMR
Dealing
Share Option Award:
IXICO plc (AIM: IXI), the medical
imaging advanced analytics company delivering insights in
neurosciences, today announces that it has issued a total of
500,000 options to subscribe for ordinary shares of 1 pence each in
the Company (the "Share
Options") to Robin Wolz, CSO and a PDMR of the
Company.
In recognition of his increasing
contribution to the continued success of the Group, the Board has
decided to provide Mr Wolz with share option performance criteria
that is aligned with the Group's Executive Directors.
The Share Options have vesting
criteria aligned with retention and annual share price growth over
3 years. These options have an exercise price of £0.01 and will be
subject to a hold period to the third anniversary of their
award.
The achievement of share price
growth each year shall be measured by calculating the 3-month
average share price immediately prior to each anniversary of the
option award. The growth performance can be met in full by an
absolute compound share price growth of 40% over the three-year
period or in part by a 40% share price growth as compared to the
prior year. In the first year this shall be compared to a baseline
price equivalent to the three-month average share price immediately
prior to the CEO joining the Company on 19 August 2024.
It is further announced that 200,000
options awarded to Mr Wolz on 30 October 2024 lapsed in full with
effect from 28 November 2024.
Director Bed & ISA Dealings:
In addition, the Company announces
that it received notification on 4 December 2024, that Grant Nash,
CFO and PDMR, sold 260,000 ordinary shares of 1p each in the
Company and repurchased 260,000 ordinary shares into Mr Nash's ISA
account. Following this transaction Mr Nash's beneficial
interest in the Company's shares has not changed.
The notifications below, made in
accordance with the requirements of the Market Abuse Regulation,
provide further detail.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan
Hodkinson (Corporate
Finance)
|
|
|
Nigel Birks (Life Sciences
Specialist Sales)
|
|
|
Harriet Ward (Corporate
Broking)
|
|
|
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on X
(formerly Twitter) @IXICOnews
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Robin Wolz
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Scientific Officer and
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares in
IXICO plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of Share Options
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
1 pence
|
500,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
N/A - single transaction
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
4 December 2024
|
|
f)
|
Place of the transaction
|
Off Market Transaction
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Grant Nash
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer and
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares in IXICO
plc
|
|
|
|
|
Identification code
|
ISIN: GB00BFXR4C20
|
|
|
|
|
b)
|
Nature of the transaction
|
Sale and purchase of ordinary
shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
Sale at 12.000p
|
260,000
|
|
|
|
|
Purchase at 12.015p
|
260,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
N/A
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
4 December 2024
|
|
f)
|
Place of the transaction
|
Off Market Transaction
|